# A Study of Benmelstobart, Anlotinib, Chemotherapy and Thoracic Radiotherapy for People With Extensive-stage Small Cell Lung Cancer

> **NCT07538271** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Yayi He** · enrollment: 33 (estimated)

## Conditions studied

- SCLC, Extensive Stage

## Interventions

- **DRUG:** benmelstobart
- **DRUG:** Anlotinib
- **DRUG:** Carboplatin or cisplatin
- **DRUG:** Etoposide
- **RADIATION:** Thoracic Radiotherapy

## Key facts

- **NCT ID:** NCT07538271
- **Lead sponsor:** Yayi He
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-20
- **Primary completion:** 2027-09-30
- **Final completion:** 2029-03-31
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2026-04-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07538271

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07538271, "A Study of Benmelstobart, Anlotinib, Chemotherapy and Thoracic Radiotherapy for People With Extensive-stage Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07538271. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*